JPRN-UMIN000015765已完成未知
A Phase II Study of Capecitabine, Oxaliplatin (XELOX) and Bevacizumab for patient with high-risk Upper Rectal Cancer as Neo-Adjuvant chemotherapy. - COBURA study
Cancer Institute Hospital of Japanese Foundation for Cancer Research0 个研究点目标入组 19 人开始时间: 2014年12月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 19
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Malignant coelomic fluid. 2. Multiple primary cancer within 5 years. 3. History of intrapelvic irradiation. 4. Clinically significant complication (heart failure, interstitial lung disease or pulmonary fibrosis, uncontrolled diabetes, renal failure, liver failure, etc.) 5. History of the serious hypersensitivity for any agents. 6. Uncontrolled diarrhea. 7. Evidence of peripheral sensory neuropathy. 8. Uncontrolled Active infection. 9. Other conditions not suitable for this study.
研究者
相似试验
已完成
不适用
Phase II study of Capecitabine + oxaliplatin(CapeOx) for elderly patients with untreated metastatic gastric cancer <TCOG GI-1601>ntreated metastatic gastric cancerJPRN-UMIN000022450The Tokyo Cooperative Oncology Group110
招募中
2 期
A phase II trial of oxaliplatin, capecitabine, irinotecan (XELOXIRI) and bevacizumab as first-line therapy for patients with metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000039783Sapporo Medical University School of Medicine47
已完成
不适用
A phase II study of capecitabin plus oxaliplatin therapy (XELOX) for inoperable/advanced gastric cancer resistant/intolerable to fluoro-pyrimidine, CDDP, Taxane or CPT-11 (OGSG1403)unresectable/advanced gastric cancerJPRN-UMIN000016256Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)12
已完成
2 期
P II study of CapeOX therapy for small intestinal cancerunresectable or recurrent small bowel adenocarcinoma with no prior treatmentJPRN-jRCTs041180011Yasui Hirofumi17
招募中
4 期
Cohort study of capecitabine plus oxaliplatin (XELOX) together with Bevacizumab as the first-line therapy in advance or recurrent colorectal cancer.Advance or recurrent colorectal cancer.JPRN-UMIN000006057Tokyo Medical University The third department of surgery30